ImmuPharma (LON:IMM) Stock Price Up 12.2% – Time to Buy?

ImmuPharma plc (LON:IMM)’s stock price rose 12.2% on Friday . The company traded as high as GBX 1.71 ($0.02) and last traded at GBX 1.71 ($0.02). Approximately 1,042,772 shares changed hands during trading, a decline of 83% from the average daily volume of 6,114,129 shares. The stock had previously closed at GBX 1.52 ($0.02).

ImmuPharma Trading Up 5.3%

The firm has a market cap of £6.80 million, a price-to-earnings ratio of -2.77 and a beta of 1.53. The business’s 50-day simple moving average is GBX 2.14 and its two-hundred day simple moving average is GBX 2.87.

ImmuPharma (LON:IMM) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) (($0.01)) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.